Clinical and pathological features of renal epithelioid angiomyolipoma (PEComa): A single institution series.

[1]  T. Antic,et al.  Eosinophilic Renal Cell Tumors With a TSC and MTOR Gene Mutations Are Morphologically and Immunohistochemically Heterogenous , 2020, The American journal of surgical pathology.

[2]  T. Deguchi,et al.  Metastatic epithelioid angiomyolipoma treated with everolimus in a patient receiving hemodialysis: A case report , 2019, IJU case reports.

[3]  D. Doval,et al.  Case report of everolimus-induced sustained partial response in metastatic renal epithelioid angiomyolipoma. , 2018, Turkish journal of urology.

[4]  M. Voss,et al.  Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy , 2018, Journal of Immunotherapy for Cancer.

[5]  D. Quinlan,et al.  Pulmonary metastasis from renal epithelioid angiomyolipoma in the setting of breast cancer , 2017, BMJ Case Reports.

[6]  C. Antonescu,et al.  TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers , 2016, The American journal of surgical pathology.

[7]  C. Fisher,et al.  PEComa: morphology and genetics of a complex tumor family. , 2015, Annals of diagnostic pathology.

[8]  Y. Sevim,et al.  Renal Angiomyolipoma With Caval Extension and Pulmonary Fat Embolism , 2015, Medicine.

[9]  R. Arpacı,et al.  Malignant epitheloid angiomyolipoma of the kidney in a child treated with sunitinib, everolimus and axitinib. , 2015, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[10]  Hao Ning,et al.  Invasive Epithelioid Angiomyolipoma with Tumor Thrombus in the Inferior Vena Cava: A Case Report and Literature Review , 2015, Urologia Internationalis.

[11]  A. Sangoi,et al.  Tuberous Sclerosis–associated Renal Cell Carcinoma: A Clinicopathologic Study of 57 Separate Carcinomas in 18 Patients , 2014, The American journal of surgical pathology.

[12]  Z. Tsuchihashi,et al.  Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy. , 2014, American journal of physiology. Renal physiology.

[13]  R. Nussbaum,et al.  Renal Cell Carcinoma in Tuberous Sclerosis Complex , 2014, The American journal of surgical pathology.

[14]  Tze Hau Lam,et al.  Mapping the p53 transcriptome universe using p53 natural polymorphs , 2013, Cell Death and Differentiation.

[15]  S. Matin,et al.  Malignant epithelioid angiomyolipoma: tumor and metabolic response to everolimus as evaluated with positron emission tomography. , 2013, Clinical genitourinary cancer.

[16]  M. Frey,et al.  Up-Regulation of Two Distinct p53-DNA Binding Functions by Covalent Poly(ADP-ribosyl)ation: Transactivating and Single Strand Break Sensing , 2013, Cancer investigation.

[17]  T. Yamasaki,et al.  Role of mammalian target of rapamycin inhibitor in the treatment of metastatic epithelioid angiomyolipoma: A case report , 2013, International journal of urology : official journal of the Japanese Urological Association.

[18]  J. Drabick,et al.  Fatal Malignant Metastastic Epithelioid Angiomyolipoma Presenting in a Young Woman: Case Report and Review of the Literature , 2013, Rare tumors.

[19]  J. Cheville,et al.  Epithelioid angiomyolipoma of the kidney: pathological features and clinical outcome in a series of consecutively resected tumors , 2013, Modern Pathology.

[20]  David Chen,et al.  Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial , 2013, The Lancet.

[21]  Jun Li,et al.  Malignant epithelioid angiomyolipoma of the kidney with pulmonary metastases and p53 gene mutation , 2012, World Journal of Surgical Oncology.

[22]  A. Folpe,et al.  “Malignant” Perivascular Epithelioid Cell Neoplasm: Risk Stratification and Treatment Strategies , 2012, Sarcoma.

[23]  Y. Yatabe,et al.  Dramatic tumor response to everolimus for malignant epithelioid angiomyolipoma. , 2011, Japanese journal of clinical oncology.

[24]  Joost Schymkowitz,et al.  Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. , 2011, Nature chemical biology.

[25]  A. Gown,et al.  Pure Epithelioid PEComas (So-Called Epithelioid Angiomyolipoma) of the Kidney: A Clinicopathologic Study of 41 Cases: Detailed Assessment of Morphology and Risk Stratification , 2011, The American journal of surgical pathology.

[26]  B. Bui,et al.  Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  J. Epstein,et al.  Renal Epithelioid Angiomyolipoma With Atypia: A Series of 40 Cases With Emphasis on Clinicopathologic Prognostic Indicators of Malignancy , 2010, The American journal of surgical pathology.

[28]  J. Brugarolas,et al.  Sirolimus and temsirolimus for epithelioid angiomyolipoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  S. Yara,et al.  Malignant epithelioid angiomyolipoma in the kidney and liver of a patient with pulmonary lymphangioleiomyomatosis: lack of response to sirolimus. , 2009, Internal medicine.

[30]  C. Pan,et al.  Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma , 2008, The Journal of pathology.

[31]  E. Halpern,et al.  Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors. , 2006, Kidney international.

[32]  Antonio Lopez-Beltran,et al.  2004 WHO classification of the renal tumors of the adults. , 2006, European urology.

[33]  M. Hayama,et al.  Angiomyolipoma of kidney involving the inferior vena cava , 2004, International journal of urology : official journal of the Japanese Urological Association.

[34]  Erwin G. Van Meir,et al.  Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion. , 2002, Cancer research.

[35]  J. Eble,et al.  Oncocytoma-like angiomyolipoma. A clinicopathologic and immunohistochemical study of 2 cases. , 2002, Archives of pathology & laboratory medicine.

[36]  Tsuyoshi Saito,et al.  Malignant Transformation of Renal Angiomyolipoma: A Case Report , 2002, The American journal of surgical pathology.

[37]  A. Folpe.  Neoplasms with perivascular epithelioid cell differentiation (PEComas) , 2002 .

[38]  A. Gown,et al.  Renal angiomyolipoma: further immunophenotypic characterization of an expanding morphologic spectrum. , 2001, Archives of pathology & laboratory medicine.

[39]  E. Henske,et al.  Renal angiomyolipomas, cysts, and cancer in tuberous sclerosis complex. , 1998, Seminars in pediatric neurology.

[40]  E. Henske,et al.  Apparent renal cell carcinomas in tuberous sclerosis are heterogeneous: the identification of malignant epithelioid angiomyolipoma. , 1998, The American journal of surgical pathology.

[41]  M. Amin,et al.  Epithelioid angiomyolipoma of the kidney: a report of five cases with a prominent and diagnostically confusing epithelioid smooth muscle component. , 1997, The American journal of surgical pathology.

[42]  K. Mai,et al.  Epithelioid cell variant of renal angiomyolipoma , 1996, Histopathology.

[43]  Y. Fujii,et al.  Benign renal tumors detected among healthy adults by abdominal ultrasonography. , 1995, European urology.

[44]  F. W. Foote,et al.  Angiomyolipoma of the kidney: report of 27 cases and review of the literature. , 1969, The Journal of urology.